Catalyst
Slingshot members are tracking this event:
FDA Advisory committee meeting for Sarepta Therapeutics' Eteplirsen
Do you think this event is important to the companies below? How will it affect their stock price?
Additional Information
Slingshot Insights Explained
Catalyst Date
Occurred on:
Apr 25, 2016
Occurred Source:
http://investorrelations.sarepta.com/phoenix.zhtml?c=64231&p=irol-newsArticle&ID=2161215
Related Projects
- A focused analysis of Eteplirsen after the briefing documents come out for the January 22nd Ad-COM. Specifically how the additional information influences the expert's view on the chance of a positive vote from the committee. SRPT, BMRN, PTCT Executed On: Jan 19, 2016 at 01:00 PM EST
- On the eve of the Biomarin's Duchenne Muscular Dystrophy (DMD) advisory panel for Drisapersen, a conversation about the disease, patients and the chance of approval BMRN, SRPT, PTCT Executed On: Nov 13, 2015 at 03:00 PM EST
Related Keywords
Dmd, Duchenne Muscular Dystrophy, Eteplirsen, Advisory Panel, Drisapersen
